The top 3 holdings of LABU are Alnylam Pharmaceuticals (ALNY) (2.235%), Insmed (INSM) (1.931%) and Halozyme Therapeutics (HALO) (1.898%).

FUND	HOLDING	% OF FUND	VALUE ($)
LABU	Alnylam Pharmaceuticals (ALNY)	2.235%	$14.4M
LABU	Insmed (INSM)	1.931%	$12.5M
LABU	Halozyme Therapeutics (HALO)	1.898%	$12.2M
LABU	Incyte (INCY)	1.794%	$11.6M
LABU	Regeneron Pharmaceuticals (REGN)	1.647%	$10.6M
LABU	United Therapeutics (UTHR)	1.604%	$10.3M
LABU	AbbVie (ABBV)	1.562%	$10.1M
LABU	Neurocrine Biosciences (NBIX)	1.555%	$10M
LABU	Gilead Sciences (GILD)	1.517%	$9.8M
LABU	Biogen (BIIB)	1.492%	$9.6M
LABU	Madrigal Pharmaceuticals (MDGL)	1.483%	$9.6M
LABU	BridgeBio Pharma (BBIO)	1.468%	$9.5M
LABU	Biomarin Pharmaceutical (BMRN)	1.45%	$9.4M
LABU	Amgen (AMGN)	1.447%	$9.3M
LABU	Natera (NTRA)	1.386%	$8.9M
LABU	Moderna (MRNA)	1.349%	$8.7M
LABU	Exelixis (EXEL)	1.334%	$8.6M
LABU	Vertex Pharmaceuticals (VRTX)	1.253%	$8.1M
LABU	EXACT Sciences (EXAS)	1.197%	$7.7M
LABU	Roivant Sciences (ROIV)	1.036%	$6.7M
LABU	Cytokinetics (CYTK)	0.958%	$6.2M
LABU	Ionis Pharmaceuticals (IONS)	0.929%	$6M
LABU	Crispr Therapeutics (CRSP)	0.897%	$5.8M
LABU	Avidity Biosciences (RNA)	0.841%	$5.4M
LABU	Revolution Medicines (RVMD)	0.829%	$5.3M

Holdings are tracked for approximately 2000 ETFs.